Search For "cipla limited"
Cipla Launches Win Over Weight Campaign, Igniting a National Conversation
Updated : 2 months, 2 weeks ago IST
Mumbai (Maharashtra) [India], February 5: Cipla Limited (BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today announced the launch of its nationwide awareness campaign, 'Win Over Weight', designed to help people move beyond weight-focused stigma and towards improved health, c
Read More
Cipla launches Yurpeak for treatment of obesity, Type 2 diabetes
Updated : 5 months, 3 weeks ago IST
Cipla Limited on Wednesday announced the launch of Yurpeak (tirzepatide), a once-weekly injectable therapy for the management of obesity and type 2 diabetes mellitus (T2DM) -- two of the country's most pressing health challenges.
Read More
Techknowgreen Solutions Receives New Work Orders Worth Rs 34.03 Mn
Updated : 2 years, 6 months ago IST
New Delhi [India], November 22: Techknowgreen Solutions Ltd. is one of India's leading environmental consulting company, announced receiving the work order from STT Global Data Centres India Private Limited & Cipla Limited.
Read More
Cipla adds capacity of captive renewable energy power plant in Maharashtra
Updated : 3 years, 12 months ago IST
New Delhi [India], June 2 (ANI): Cipla Limited on Thursday announced the commercial operation of additional capacity of a captive renewable energy power plant in Maharashtra and Karnataka.
Read More
Cipla receives final approval for generic version of GlaxoSmithKline's IMI
Updated : 5 years, 2 months ago IST
Mumbai (Maharashtra) [India], March 2 (ANI/PRNewswire): Cipla Limited today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray, 20 mg from the United States Food and Drug Administration (U.S. FDA).
Read More
Cipla receives final approval for generic version of AstraZeneca Pharmaceu
Updated : 6 years, 2 months ago IST
Mumbai (Maharashtra) [India], Mar 27 (ANI/ PRNewswire): Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and hereafter referred to as "Cipla" today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Esomeprazole for Oral Suspension 10mg, 20mg and 40m
Read More